Shots: Takeda to receive ~$660M for divesting its 20 select prescription pharmaceutical and OTC products traded in Russia, Georgia, and several countries within the Commonwealth of Independent States. STADA to […]readmore
Tags : Divest
Shots: GSK to receive $335.9M up front, ~$552.6M milestones including $27.9M as a commercial milestone and $177.5M related to inventory, making the total value as $1B. Bavarian Nordic to get […]readmore
Shots: Takeda to receive ~$200M for divesting its 30 select prescription pharmaceutical and OTC products traded in Near East, Middle East and Africa (NEMEA) countries. Acino to get rights, title, […]readmore
Shots: Aclaris to receive $55M in cash including $35M up front and sales milestones of up to $20M apart from is eligible for royalties on sales of product-by-product and country-by-country […]readmore
Shots: AstraZeneca to receive upfront, $243M on completion of the agreement with ~33M as a commercial milestone in 2021 and 2022. Cheplapharm to get global commercial rights for Losec & […]readmore
Shots: H.I.G. Capital acquires BioVectra (a subsidiary of Mallinckrodt) for $175M fixed consideration including $135M as up front and $40M as long term note along with a contingent payment of […]readmore
Shots: BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly In Jan’2019, BMS announced to acquire Celgene with […]readmore